Abstract
Staphylococcus aureus may be a highly virulent human pathogen, especially when it is able to form a biofilm, and it is resistant to antibiotic. Infections caused by these bacteria significantly affect morbidity and mortality, primarily in hospitalized patients. Treatment becomes more expensive, more toxic, and prolonged. This is the reason why research on alternative therapies should be one of the main priorities of medicine and biotechnology. A promising alternative treatment approach is bacteriophage therapy. The effect of the anti-staphylococcal bacteriophage preparation Stafal® on biofilm reduction was assessed on nine S. aureus strains using both sonication with subsequent quantification of surviving cells on the catheter surface and evaluation of biofilm reduction in microtiter plates. It was demonstrated that the bacteriophages destroy planktonic cells very effectively. However, to destroy cells embedded in the biofilm effectively requires a concentration at least ten times higher than that provided by the commercial preparation. The catheter disc method (CDM) allowed easier comparison of the effect on planktonic cells and cells in a biofilm than the microtiter plate (MTP) method.
References
Abedon ST (2012) Spatial vulnerability: bacterial arrangements, microcolonies, and biofilms as responses to low rather than high phage densities. Viruses 4(5):663–687. https://doi.org/10.3390/v4050663
Alves DR, Gaudion A, Bean JE, Perez Esteban P, Arnot TC, Harper DR, Kot W, Hansen LH, Enright MC, Tobias A, Jenkins A (2014) Combined use of bacteriophage K and a novel bacteriophage to reduce Staphylococcus aureus biofilm formation. Appl Environ Microbiol 80(21):6694–6703. https://doi.org/10.1128/AEM.01789-14
Azeredo J, Sutherland IW (2008) The use of phages for the removal of infectious biofilms. Curr Pharm Biotechnol 9:261–266. https://doi.org/10.2174/138920108785161604
Čapla J, Zajác P, Vietoris V, Bajzík P (2010) New methodologies for biofilms control in food industry. Potravinarstvo 4(3):10–13
Cooper CJ, Khan Mirzaei M, Nilsson AS (2016) Adapting drug approval pathways for bacteriophage-based therapeutics. Front Microbiol 7:1209. https://doi.org/10.3389/fmicb.2016.01209
Cui Z, Guo X, Dong K, Dong K, Zhang Y, Li Q, Zhu Y, Zeng L, Tang R, Li L (2017) Safety assessment of Staphylococcus phages of the family Myoviridae based on complete genome sequences. Sci Rep 7:41259. https://doi.org/10.1038/srep41259
Curtin JJ, Donlan RM (2006) Using bacteriophages to reduce formation of catheter-associated biofilms by Staphylococcus epidermidis. Antimicrob Agents Chemother 50(4):1268–1275. https://doi.org/10.1128/AAC.50.4.1268-1275.2006
Debarbieux L, Pirnay JP, Verbeken G, DeVos D, Merabishvili M, Huys I, Merabishvili M, Huys I, Patey O, Schoonjans D, Vaneechoutte M, Zizi M, Rohde C (2016) A bacteriophage journey at the European Medicines Agency. FEMS Microbiol Lett 363(2):fnv225. https://doi.org/10.1093/femsle/fnv225
Drilling A, Morales S, Jardeleza C, Vreugde S, Speck P, Wormald PJ (2014) Bacteriophage reduces biofilm of Staphylococcus aureus ex vivo isolates from chronic rhinosinusitis patients. Am J Rhinol Allergy 28:3–11. https://doi.org/10.2500/ajra.2014.28.4001
Enright MC, Day NPJ, Davies CE, Peacock SJ, Spratt BG (2000) Multilocus sequence typing for characterization of methicillin-resistant and methicillin-susceptible clones of Staphylococcus aureus. J Clin Microbiol 38:1008–1015
Eyer L, Pantůček R, Zdráhal Z, Konečná H, Kašpárek P, Růžičková V, Hernychová L, Preisler J, Doškař J (2007) Structural protein analysis of the polyvalent staphylococcal bacteriophage 812. Proteomics 7:64–72. https://doi.org/10.1002/pmic.200600280
Górski A, Międzybrodzki R, Weber-Dąbrowska B, Fortuna W, Letkiewitcz S, Rogoz P, Jonczyk-Matysiak E, Dabrowska K, Majewska J, Borysowski J (2016) Phage therapy: combating infections with potential for evolving from merely a treatment for complications to targeting diseases. Front Microbiol 7:1515. https://doi.org/10.3389/fmicb.2016.01515
Hanlon GW, Denyer SP, Olliff CJ, Ibrahim LJ (2001) Reduction in exopolysaccharide viscosity as an aid to bacteriophage penetration through Pseudomonas aeruginosa biofilms. Appl Environ Microbiol 67:2746–2753. https://doi.org/10.1128/AEM.67.6.2746-2753.2001
Harmsen D, Claus H, Witte W, Rothgänger J, Claus H, Turnwald D, Vogel U (2003) Typing of methicillin-resistant Staphylococcus aureus in a university hospital setting by using novel software for spa repeat determination and database management. J Clin Microbiol 41:5442–5448. https://doi.org/10.1128/JCM.41.12.5442-5448.2003
Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC (1997) Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 40:135–136. https://doi.org/10.1093/jac/40.1.135
Hughes KA, Sutherland IW, Jones MV (1998) Biofilm susceptibility to bacteriophage attack: the role of phage-borne polysaccharide depolymerase. Microbiology 144(Pt 11):3039–3047. https://doi.org/10.1099/00221287-144-11-3039.
Kelly D, McAuliffe O, Ross RP, Coffey A (2012) Prevention of Staphylococcus aureus biofilm formation and reduction in established biofilm density using a combination of phage K and modified derivatives. Lett Appl Microbiol 54(4):286–291. https://doi.org/10.1111/j.1472-765X.2012.03205.x
Kobayashi H, Oethinger M, Tuohy MJ, Procop GW, Bauer TW (2009) Improved detection of biofilm-formative bacteria by vortexing and sonication: a pilot study. Clin Orthop Related Res 467(5):1360–1364. https://doi.org/10.1007/s11999-008-0609-5
Kvachadze L, Balarjishvili N, Meskhi T, Tevdoradze E, Skhirtladze N, Pataridze T, Adamia R, Topuria T, Kutter E, Rohde C, Kutateladze M (2011) Evaluation of lytic activity of staphylococcal bacteriophage Sb-1 against freshly isolated clinical pathogens. Microb Biotechnol 4(5):643–650. https://doi.org/10.1111/j.1751-7915.2011.00259.x
Łobocka M, Hejnowicz MS, Dąbrowski K, Gozdek A, Kosakowski J, Witkowska M, Ulatowska MI, Weber-Dąbrowska B, Kwiatek M, Parasion S, Gawor J, Kosowska H, Głowacka A (2012) Genomics of staphylococcal Twort-like phages—potential therapeutics of the post-antibiotic era. Adv Virus Res 83:143–216. https://doi.org/10.1016/B978-0-12-394438-2.00005-0
Lungren MP, Christensen D, Kankotia R, Falk I, Paxton BE, Kim CY (2013) Bacteriophage K for reduction of Staphylococcus aureus biofilm on central venous catheter material. Bacteriophage 3(4):e26825. https://doi.org/10.4161/bact.26825
Milheiriço C, Oliveira DC, de Lencastre H (2007) Update to the multiplex PCR strategy for assignment of mec element types in Staphylococcus aureus. Antimicrob Agents Chemother 51:3374–3377. https://doi.org/10.1128/AAC.00275-07
Nováček J, Šiborová M, Benešík M, Pantůček R, Doškař J, Plevka P (2016) Structure and genome release of Twort-like Myoviridae phage with a double-layered baseplate. Proc Natl Acad Sci U S A 113(33):9351–9356. https://doi.org/10.1073/pnas.1605883113
O’Flaherty S, Ross RP, Meaney W, Fitzgerald GF, Elbreki MF, Coffey A (2005) Potential of the polyvalent anti-Staphylococcus bacteriophage K for control of antibiotic-resistant staphylococci from hospitals. Appl Environ Microbiol 71:1836–1842. https://doi.org/10.1128/AEM.71.4.1836-1842.2005
Oliveira H, Sillankorva S, Merabishvili M, Kluskens LD, Azeredo J (2015) Unexploited opportunities for phage therapy. Front Pharmacol 6:180. https://doi.org/10.3389/fphar.2015.00180
Pantůček R, Rosypalová A, Doškar J, Kailerová J, Ružičková V, Borecká P, Snopková S, Horváth R, Götz F, Rosypal S (1998) The polyvalent staphylococcal phage phi 812: its host-range mutants and related phages. Virology 246(2):241–252. https://doi.org/10.1006/viro.1998.9203
Pillich J, Výmola F, Buda J (1969) Assumptions for successful therapy using staphylococcal phage lysates. Zentralbl Bakteriol Orig A 210(3):377–381
Pulverer G, Pillich J, Kocur M (1966) Zwei neue gegen pathogene Staphylokokken wirksame Bakteriophagen. Zentralbl Bakteriol Parasit Infekt Hyg I Orig 201:321–325
Rahman M, Kim S, Kim SM, Seol SY, Kim J (2011) Characterization of induced Staphylococcus aureus bacteriophage SAP-26 and its anti-biofilm activity with rifampicin. Biofouling 27:1087–1093. https://doi.org/10.1080/08927014.2011.631169
Seth AK, Geringer MR, Nguyen KT, Agnew SP, Dumanian Z, Galiano RD, Leung KP, Mustoe TA, Hong SJ (2013) Bacteriophage therapy for Staphylococcus aureus biofilm-infected wounds: a new approach to chronic wound care. Plast Reconstr Surg 131:225–234. https://doi.org/10.1097/PRS.0b013e31827e47cd
Son JS, Lee SJ, Jun SY, Yoon SJ, Kang SH, Paik HR, Kang JO, Choi YJ (2010) Antibacterial and biofilm removal activity of a podoviridae Staphylococcus aureus bacteriophage SAP-2 and a derived recombinant cell-wall-degrading enzyme. Appl Microbiol Biotechnol 86(5):1439–1449. https://doi.org/10.1007/s00253-009-2386-9
Stepanović S, Vuković D, Hola V, Di Bonaventura G, Djukić S, Cirković I, Ruzicka F (2007) Quantification of biofilm in microtiter plates: overview of testing conditions and practical recommendations for assessment of biofilm production by staphylococci. APMIS 115:891–899. https://doi.org/10.1111/j.1600-0463.
Sutherland IW, Hughes KA, Skillman LC, Tait K (2004) The interaction of phage and biofilms. FEMS Microbiol Lett 232:1–6. https://doi.org/10.1016/S0378-1097(04)00041-2.
Swenson JM, Tenover FC (2005) Cefoxitin disk study group, results of disk diffusion testing with cefoxitin correlate with presence of mecA in Staphylococcus spp. J Clin Microbiol 43(8):3818–3823. https://doi.org/10.1128/JCM.43.8.3818-3823.2005.
Vandersteegen K, Mattheus W, Ceyssens P-J, Bilocq F, De Vos D, Pirnay JP, Noben JP, Merabishvili M, Lipinska U, Hermans K, Lavigne R (2011) Microbiological and molecular assessment of bacteriophage ISP for the control of Staphylococcus aureus. Fitzgerald JR, ed PLoS ONE 6(9):e24418. doi: 10.1371/journal.pone.0024418
Funding
This work was supported by the Ministry of Health of the Czech Republic, grant no. 16-29916A.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Dvořáčková, M., Růžička, F., Benešík, M. et al. Antimicrobial effect of commercial phage preparation Stafal® on biofilm and planktonic forms of methicillin-resistant Staphylococcus aureus. Folia Microbiol 64, 121–126 (2019). https://doi.org/10.1007/s12223-018-0622-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12223-018-0622-3